Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer.

Cancer shared this article with you from Inoreader Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer. Via The Oncologist CONCLUSIONS: Tumor FSP correlated with prolonged efficacy of anti-PD1 treatment among patients with dMMR cancers, and may represent a new biomarker of immune checkpoint inhibitor sensitivity. IMPLICATIONS FOR PRACTICE: Given the modest efficacy of immune checkpoint inhibition (ICI) in unselected patients with advanced prostate cancer, biomarkers of ICI sensitivity are needed. To facilitate biomarker discovery, we assembled a cohort of patients with DNA mismatch repair-deficient (dMMR) prostate cancer as these patients are enriched for responses to ICI. We observed a high response rate to anti-PD1 therapy in these patients, however these responses were not durable in most patients. Notably, we identified tumor frameshift mutation proportion (FSP) as a novel biomarker that was associated... View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.